# A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

> **NCT06642961** · PHASE2 · UNKNOWN · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GR1802 injection
- **DRUG:** GR1802 injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06642961
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-19
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06642961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06642961, "A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06642961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*